Lorenzo Corsini

Company: BioNTech

Job title: Managing Director

Seminars:

Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance 1:30 pm

Bacterial vaginosis is the most frequent vaginal infection; standard of care antibiotics suffer from antimicrobial resistance formation and weak biofilm activity The phage-derived, engineered endolysin PM-477 is not prone to resistance formation and highly active on biofilms in vitro and on human material ex vivo PM-477 is being developed as an intravaginal tablet for the…Read more

day: Day Two

Panel Discussion: Overcoming Barriers in Securing Funding & Questioning the Investment Process…Worth Billions or Nothing? 11:00 am

Explaining the sudden dry up of funds Learning how investors value an early-stage phage business that could make or break it Understanding what makes an attractive proposition when looking at investing in life science phage therapies How does funding capital differ for different bacteriophage therapiesRead more

day: Day Two